Drugs / ACT-462206
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01954589 | Nov 2011 → Jan 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-462206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01954589 ↗ |
| Action | Inhibit | “ACT-462206, a novel dual orexin receptor antagonist” NCT01954589 ↗ |
| Modality | Small molecule | — CHEMBL3597952 ↗ |
| Route | Oral | “6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo” NCT01954589 ↗ |